Welcome to “A to Z: Drugs in Highlight”
This series is designed to delve into the intricate realm of pharmaceutical drugs. As the world of pharmaceuticals continues to evolve with new discoveries and emerging challenges, we aim to shed light on the diverse array of medications available today, ranging from blockbuster medications to those that may not be as familiar. Whether you’re a healthcare professional, a student, or simply someone with a curious mind, “A to Z: Drugs in Highlight” promises to be an enlightening and engaging series.
F is for FERRIPROX®!
FERRIPROX® (from Chiesi Farmaceutici S.p.A) uses deferiprone for treating thalassaemia. It is available as tablets (500 and 1000 mg) and as an oral solution (100 mg/ml).
How FERRIPROX® works:
FERRIPROX® contains the active substance deferiprone. Deferiprone is an iron chelator that is used to treat an excess of iron in the body in patients with thalassaemia, which is an inherited disease where patients are unable to make enough haemoglobin. Removing iron in this way helps correct the iron overload and prevent damage from excess iron.
FERRIPROX® Marketing approval:
FERRIPROX® is approved for marketing in both the United States (approved by the FDA in October 2011 (tablet), September 2015 (solution) and May 2020 (tablet)) and Europe (approved by the EMA in August 1999).
FERRIPROX® Patent protection:
There are patent rights protecting aspects of FERRIPROX® in the United States and Europe (as well as in many other countries around the world). For example, granted US patent no. 8703156 and granted European patent number 2268282 relate to an oral pharmaceutical liquid formulation comprising deferiprone in a concentration of about 20 grams to about 200 grams per litre of liquid formulation and a taste masking composition.